A Phase I Dose Escalation Study of Repeated Administration of "CYT107" (glyco-r-hIL-7) Add On Treatment in Genotype 1 HCV Infected Patients Resistant to 12 Weeks Peg-Interferon-Alpha / Ribavirin.
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Interleukin-7; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms ECLIPSE-1
- Sponsors Cytheris
- 07 Dec 2009 Additional trial identifier NCT01025596 identified and inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
- 06 Dec 2009 Additional lead trial centresand investigators identified as reported by ClinicalTrials.gov.
- 06 Dec 2009 New source identified and integrated (ClinicalTrials.gov record no. NCT01025596).